Showing results (231-240 of 793) with videos related to

Sort By:
Pageof 80
Cancer Biology & Therapy|June 2, 2016
Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myelomaKatelyn G Ponder, Shannon M Matulis, Sadae Hitosugi, et al.
Blood|December 2, 2006
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective studyAsher A Chanan-Khan, Jonathan L Kaufman, Jayesh Mehta, et al.
Scientific Reports|February 13, 2024
Majority of human circulating IgG plasmablasts stop blasting in a cell-free pro-survival cultureDoan C Nguyen, Celia Saney, Ian T Hentenaar, et al.
British Journal of Haematology|May 4, 2011
Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 studyPaul G Richardson, Asher A Chanan-Khan, Sagar Lonial, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2024
Navigating High-Risk and Ultrahigh-Risk Multiple Myeloma: Challenges and Emerging StrategiesMatthew J Rees, Mattia D'Agostino, Lisa B Leypoldt, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 9, 2025
Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral AbstractSara A Scott, Danielle L Roberts, Vikas A Gupta, et al.
Blood|June 11, 2011
Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cellsAlejo A Morales, Metin Kurtoglu, Shannon M Matulis, et al.
The Annals of Pharmacotherapy|November 22, 2013
Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferencesMeagan S Barbee, R Donald Harvey, Sagar Lonial, et al.
Haematologica|September 4, 2025
Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experienceLorenzo Cani, Sara A Scott, Danielle Roberts, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 18, 2021
Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaAndrzej Jakubowiak, Saad Z Usmani, Amrita Krishnan, et al.
Pageof 80